Intra-Cellular Therapies, Inc.

Quick facts

Phase 3 pipeline

• ITI-007 (Lumateperone) · Psychiatry / Neurology
  Lumateperone is a serotonin 5-HT7 receptor antagonist and phosphodiesterase 1 inhibitor that modulates intracellular signaling pathways implicated in psychosis and mood disorders.
• Lumateperone high dose · Psychiatry / Neurology
  Lumateperone is a serotonin 5-HT7 receptor antagonist and phosphodiesterase 10 (PDE10) inhibitor that modulates dopamine and glutamate signaling in the brain.
• Lumateperone (ITI-007) · Psychiatry
  Lumateperone is a serotonin-dopamine antagonist that modulates glutamatergic neurotransmission.
• Lumateperone low dose · Psychiatry
  Lumateperone is a serotonin-dopamine antagonist that modulates glutamatergic neurotransmission.

Phase 2 pipeline

• ITI-1284

Phase 1 pipeline

• [14C]-ITI-1284
• ITI-214
• ITI-333
• Lumateperone Capsule
• Lumateperone LAI
• Lumateperone Long-Acting Injectable

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Intra-Cellular Therapies, Inc. portfolio CI brief
• Intra-Cellular Therapies, Inc. pipeline updates RSS